Mefloquine

Last updated
Mefloquine
(RS,SR)-mefloquine.svg
(RS,SR)-mefloquine ball-and-stick model.png
Clinical data
Trade names Lariam, Mephaquin, Mefliam, others
AHFS/Drugs.com Monograph
MedlinePlus a603030
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Extensive liver; main metabolite is inactive
Elimination half-life 2 to 4 weeks
Excretion Primarily bile and feces; urine (9% as unchanged drug, 4% as primary metabolite)
Identifiers
  • [(R*,S*)-2,8-Bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
Chemical and physical data
Formula C17H16F6N2O
Molar mass 378.318 g·mol−1
3D model (JSmol)
Chirality Racemic mixture
  • FC(F)(F)c2cccc1c(cc(nc12)C(F)(F)F)[C@H](O)[C@@H]3NCCCC3
  • InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m1/s1 Yes check.svgY
  • Key:XEEQGYMUWCZPDN-DOMZBBRYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Mefloquine, sold under the brand name Lariam among others, is a medication used to prevent or treat malaria. [4] When used for prevention it is typically started before potential exposure and continued for several weeks after potential exposure. [4] It can be used to treat mild or moderate malaria but is not recommended for severe malaria. [4] It is taken by mouth. [4]

Contents

Common side effects include vomiting, diarrhea, headaches, sleep disorders, and a rash. [4] Serious side effects include potentially long-term mental health problems such as depression, hallucinations, and anxiety and neurological side effects such as poor balance, seizures, and ringing in the ears. [4] It is therefore not recommended in people with a history of mental health problems or epilepsy. [4] It appears to be safe during pregnancy and breastfeeding. [1]

Mefloquine was developed by the United States Army in the 1970s and came into use in the mid-1980s. [5] [6] [7] It is on the World Health Organization's List of Essential Medicines. [8] [9] It is available as a generic medication. [4]

Medical uses

Mefloquine (Lariam) 250mg tablets Lariam.JPG
Mefloquine (Lariam) 250mg tablets

Mefloquine is used to both prevent and treat certain forms of malaria. [10]

Malaria prevention

Mefloquine is useful for the prevention of malaria in all areas except for those where parasites may have resistance to multiple medications, [11] and is one of several anti-malarial medications recommended by the United States Centers for Disease Control and Prevention for this purpose. It is also recommended by the Infectious Disease Society of America for malaria prophylaxis as a first or second-line agent, depending on resistance patterns in the malaria found in the geographic region visited. [12] [13] It is typically taken for one to two weeks before entering an area with malaria. [10] Doxycycline and atovaquone/proguanil provide protection within one to two days and may be better tolerated. [14] [15] If a person becomes ill with malaria despite prophylaxis with mefloquine, the use of halofantrine and quinine for treatment may be ineffective. [16] : 4 

Malaria treatment

Mefloquine is used as a treatment for chloroquine-sensitive or resistant Plasmodium falciparum malaria, and is deemed a reasonable alternative for uncomplicated chloroquine-resistant Plasmodium vivax malaria. [10] [16] It is one of several drugs recommended by the United States' Centers for Disease Control and Prevention. [17] It is not recommended for severe malaria infections, particularly infections from P. falciparum, which should be treated with intravenous antimalarials. [10] [16] Mefloquine does not eliminate parasites in the liver phase of the disease, and people with P. vivax malaria should be treated with a second drug that is effective for the liver phase, such as primaquine. [16] : 4 

Resistance to mefloquine

Resistance to mefloquine is common around the west border in Cambodia and other parts of Southeast Asia. [18] The mechanism of resistance is by increase in Pfmdr1 copy number. [19]

Adverse effects

Common side effects include vomiting, diarrhea, headaches, and a rash. [4] Severe side effects requiring hospitalization are rare, [11] but include mental health problems such as depression, hallucinations, anxiety and neurological side effects such as poor balance, seizures, and ringing in the ears. [4] Mefloquine is therefore not recommended in people with a history of psychiatric disorders or epilepsy. [4]

Neurologic and psychiatric

In 2013, the U.S. Food and Drug Administration (FDA) added a boxed warning to the prescription label of mefloquine regarding the potential for neuropsychiatric side effects that may persist even after discontinuing administration of the medication. [20] [21] In 2013 the FDA stated "Neurologic side effects can occur at any time during drug use, and can last for months to years after the drug is stopped or can be permanent." [22] Neurologic effects include dizziness, loss of balance, seizures, and tinnitus. Psychiatric effects include nightmares, visual hallucinations, auditory hallucinations, anxiety, depression, unusual behavior, and suicidal ideations.

Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, insomnia, and vivid dreams) in up to 25%. [23] When some measure of subjective severity is applied to the rating of adverse events, about 11–17% of travelers are incapacitated to some degree. [14]

Cardiac

Mefloquine may cause abnormalities with heart rhythms that are visible on electrocardiograms. Combining mefloquine with other drugs that cause similar effects, such as quinine or quinidine, can increase these effects. Combining mefloquine with halofantrine can cause significant increases in QTc intervals. [16] : 10 

Contraindications

Mefloquine is contraindicated in those with a previous history of seizures or a recent history of psychiatric disorders. [10]

Pregnancy and breastfeeding

Available data suggests that mefloquine is safe and effective for use by pregnant women during all trimesters of pregnancy, [24] and it is widely used for this indication. [25] In pregnant women, mefloquine appears to pose minimal risk to the fetus, [25] [26] and is not associated with increased risk of birth defects or miscarriages. [27] Compared to other malaria chemoprophylaxis regimens, however, mefloqinone may produce more side effects in non-pregnant travelers.

Mefloquine is also safe and effective for use during breastfeeding, [24] though it appears in breast milk in low concentrations. [11] [16] : 9  The World Health Organization (WHO) gives approval for the use of mefloquine in the second and third trimesters of pregnancy and use in the first trimester does not mandate termination of pregnancy. [11]

Pharmacology

Elimination

Mefloquine is metabolized primarily through the liver. Its elimination in persons with impaired liver function may be prolonged, resulting in higher plasma levels and an increased risk of adverse reactions. The mean elimination plasma half-life of mefloquine is between two and four weeks. Total clearance is through the liver, and the primary means of excretion is through the bile and feces, as opposed to only 4% to 9% excreted through the urine. During long-term use, the plasma half-life remains unchanged. [28] [29]

Liver function tests should be performed during long-term administration of mefloquine. [30] Alcohol use should be avoided during treatment with mefloquine. [31]

Chemistry

Specifically it is used as mefloquine hydrochloride.

Mefloquine is a chiral molecule with two asymmetric carbon centres, which means it has four different stereoisomers. The drug is currently manufactured and sold as a racemate of the (R,S)- and (S,R)-enantiomers by Hoffmann-La Roche, a Swiss pharmaceutical company. Essentially, it is two drugs in one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer. [14]

History

Mefloquine was formulated at Walter Reed Army Institute of Research (WRAIR) in the 1970s shortly after the end of the Vietnam war. Mefloquine was number 142,490 of a total of 250,000 antimalarial compounds screened during the study. [5]

Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman-LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. [5]

The drug was first approved in Switzerland in 1984 by Hoffmann-LaRoche, [32] who brought it to market with the name Lariam. [33]

However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. [5] Because of the drug's very long half-life, the Centers for Disease Control originally recommended a mefloquine dosage of 250 mg every two weeks; however, this caused an unacceptably high malaria rate in the Peace Corps volunteers who participated in the approval study, so the drug regimen was switched to once a week. [14]

By 1991, Hoffman was marketing the drug on a worldwide basis. [33]

By the 1992 UNITAF, Canadian soldiers were being prescribed the drug en masse. [34]

By 1994, medical professionals were noting "severe psychiatric side effects observed during prophylaxis and treatment with mefloquine", and recommending that "the absence of contraindications and minor side effects during an initial course of mefloquine should be confirmed before another course is prescribed." [35] Other doctors at the University Hospital of Zurich noted in a case of "a 47-year-old, previously healthy Japanese tourist" who had severe neuropsychiatric side-effects from the drug that [36]

The neuropsychiatric side effects of the antimalarial drug mefloquine are well documented. They include anxiety, depression, hallucinations, acute psychosis, and seizures. The incidence of these side effects is 1 in 13,000 with prophylactic use and 1 in 250 with therapeutic use.

The first randomized, controlled trial on a mixed population was performed in 2001. Prophylaxis with mefloquine was compared to prophylaxis with atovaquone-proguanil. Roughly 67% of participants in the mefloquine arm reported greater than or equal to one adverse event, versus 71% in the atovaquone-proguanil arm. In the mefloquine arm, 5% of the users reported severe events requiring medical attention, versus 1.2% in the atovaquone-proguanil arm. [5] [37]

In August 2009, Roche stopped marketing Lariam in the United States. [38]

Retired soldier Johnny Mercer, who was later appointed Minister for Veterans Affairs by Boris Johnson, told in 2015 that he had received "a letter about once or twice a week" about ill-effects from the drug. [39] In July 2016, Roche took this brand off the market in Ireland. [38]

Military

In 2006, the Australian military deemed mefloquine "a third-line drug" alternative, and over the five years from 2011 only 25 soldiers had been prescribed the drug, and only in cases of their intolerance for other alternatives. [38] Between 2001 and 2012, 16,000 Canadian soldiers sent to Afghanistan were given the drug as a preventative measure. [38] In 2013, the US Army banned mefloquine from use by its special forces such as the Green Berets. [38] In autumn 2016, the UK military followed suit with their Australian peers after a parliamentary inquiry into the matter revealed that it can cause permanent side effects and brain damage. [38]

In early December 2016, the German defence ministry removed mefloquine from the list of medications it would provide to its soldiers. [38]

In autumn 2016, Canadian Surgeon General Brigadier General Hugh Colin MacKay told a parliamentary committee that faulty science supported the assertion that the drug has indelible noxious side effects. An expert from Health Canada named Barbara Raymond told the same committee that the evidence she had read failed to support the conclusion of indelible side effects. [38] Canadian soldiers who took mefloquine when deployed overseas have claimed they have been left with ongoing mental health problems. [40]

In 2020 the UK Ministry of Defence (MoD) admitted to a breach of duty regarding the use of Mefloquine. [41] by acknowledging numerous instances of failure to assess the risks and warn of potential side effects of the drug.

Research

In June 2010, the first case report appeared of a progressive multifocal leukoencephalopathy being successfully treated with mefloquine. Mefloquine can also act against the JC virus. Administration of mefloquine seemed to eliminate the virus from the patient's body and prevented further neurological deterioration. [42]

Mefloquine alters cholinergic synaptic transmission through both postsynaptic [43] and presynaptic actions. [44] The postsynaptic action to inhibit acetylcholinesterase changes transmission across synapses in the brain. [45]

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

<span class="mw-page-title-main">Quinine</span> Medication used to treat malaria and babesiosis

Quinine is a medication used to treat malaria and babesiosis. This includes the treatment of malaria due to Plasmodium falciparum that is resistant to chloroquine when artesunate is not available. While sometimes used for nocturnal leg cramps, quinine is not recommended for this purpose due to the risk of serious side effects. It can be taken by mouth or intravenously. Malaria resistance to quinine occurs in certain areas of the world. Quinine is also used as an ingredient in tonic water to impart a bitter taste.

Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs. Incidence and distribution of the disease is expected to remain high, globally, for many years to come; moreover, known antimalarial drugs have repeatedly been observed to elicit resistance in the malaria parasite—including for combination therapies featuring artemisinin, a drug of last resort, where resistance has now been observed in Southeast Asia. As such, the needs for new antimalarial agents and new strategies of treatment remain important priorities in tropical medicine. As well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses.

<span class="mw-page-title-main">Salbutamol</span> Medication

Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, is a medication that opens up the medium and large airways in the lungs. It is a short-acting β2 adrenergic receptor agonist which works by causing relaxation of airway smooth muscle. It is used to treat asthma, including asthma attacks and exercise-induced bronchoconstriction, as well as chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebulizer, but it is also available in a pill, liquid, and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.

<span class="mw-page-title-main">Travel medicine</span> Branch of medicine

Travel medicine or emporiatrics is the branch of medicine that deals with the prevention and management of health problems of international travelers.

<span class="mw-page-title-main">Artesunate</span> Chemical compound

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

<span class="mw-page-title-main">Chloroquine</span> Medication used to treat malaria

Chloroquine is a medication primarily used to prevent and treat malaria in areas where malaria remains sensitive to its effects. Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication. Chloroquine is also occasionally used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus. While it has not been formally studied in pregnancy, it appears safe. It was studied to treat COVID-19 early in the pandemic, but these studies were largely halted in the summer of 2020, and is not recommended for this purpose. It is taken by mouth.

<span class="mw-page-title-main">Primaquine</span> Pharmaceutical drug

Primaquine is a medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. It is an alternative treatment for Pneumocystis pneumonia together with clindamycin. It is taken by mouth.

<span class="mw-page-title-main">Proguanil</span> Chemical compound

Proguanil, also known as chlorguanide and chloroguanide, is a medication used to treat and prevent malaria. It is often used together with chloroquine or atovaquone. When used with chloroquine the combination will treat mild chloroquine resistant malaria. It is taken by mouth.

<span class="mw-page-title-main">Hydroxychloroquine</span> Antimalarial medication

Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate.

<span class="mw-page-title-main">Atovaquone</span> Antimicrobial and antiprotozoan drug

Atovaquone, sold under the brand name Mepron, is an antimicrobial medication for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP).

<span class="mw-page-title-main">Pre-exposure prophylaxis for HIV prevention</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of pre-exposure prophylaxis to prevent HIV infection, the cause of HIV/AIDS.

Malaria prophylaxis is the preventive treatment of malaria. Several malaria vaccines are under development.

<span class="mw-page-title-main">Tafenoquine</span> Antimalarial drug

Tafenoquine, sold under the brand name Krintafel among others, is a medication used to prevent and to treat malaria. With respect to acute malaria, it is used together with other medications to prevent relapse by Plasmodium vivax. It may be used to prevent all types of malaria. It is taken by mouth.

<span class="mw-page-title-main">Amodiaquine</span> Chemical compound

Amodiaquine (ADQ) is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. It is recommended to be given with artesunate to reduce the risk of resistance. Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria. Though, the WHO in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.

Atovaquone/proguanil, sold under the brand name Malarone among others, is a fixed-dose combination medication used to treat and prevent malaria, including chloroquine-resistant malaria. It contains atovaquone and proguanil. It is not recommended for severe or complicated malaria. It is taken by mouth.

Sulfadoxine/pyrimethamine, sold under the brand name Fansidar, is a combination medication used to treat malaria. It contains sulfadoxine and pyrimethamine. For the treatment of malaria it is typically used along with other antimalarial medication such as artesunate. In areas of Africa with moderate to high rates of malaria, three doses are recommended during the second and third trimester of pregnancy.

Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria. It is a combination of piperaquine and dihydroartemisinin. Specifically it is used for malaria of the P. falciparum and P. vivax types. It is taken by mouth.

Artesunate/mefloquine is a medication used to treat malaria. It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria. It is taken by mouth.

Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed-dose combination medication for the treatment of malaria. It can be used for malaria of both the P. falciparum and P. vivax types. It combines artesunate and pyronaridine. It is taken by mouth.

References

  1. 1 2 "Mefloquine (Lariam) Use During Pregnancy". Drugs.com. Retrieved 31 March 2019.
  2. ↑ "Lariam 250 mg tablets - Summary of Product Characteristics (SmPC)". (emc). 3 April 2019. Retrieved 8 September 2020.
  3. ↑ "Lariam brand of mefloquine hydrochloride tablets". DailyMed. Retrieved 9 October 2022.
  4. 1 2 3 4 5 6 7 8 9 10 11 "Mefloquine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2015-12-08. Retrieved 27 Nov 2015.
  5. 1 2 3 4 5 Croft AM (April 2007). "A lesson learnt: the rise and fall of Lariam and Halfan". Journal of the Royal Society of Medicine. 100 (4): 170–174. doi:10.1177/014107680710011411. PMC   1847738 . PMID   17404338.
  6. ↑ Ravina E (2011). The evolution of drug discovery : from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 136. ISBN   9783527326693.
  7. ↑ Farrar J, Hotez PJ, Junghanss T (2013). Manson's tropical diseases (23rd ed.). Oxford: Elsevier/Saunders. p. 569. ISBN   9780702053061.
  8. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  9. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  10. 1 2 3 4 5 "Lariam". The American Society of Health-System Pharmacists. Archived from the original on 7 January 2012. Retrieved 3 April 2011.
  11. 1 2 3 4 Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG (December 2010). "The position of mefloquine as a 21st century malaria chemoprophylaxis". Malaria Journal. 9: 357. doi: 10.1186/1475-2875-9-357 . PMC   3224336 . PMID   21143906.
  12. ↑ "www.idsociety.org" (PDF). Archived (PDF) from the original on 2015-03-19.
  13. ↑ "Malaria - Chapter 3 - 2014 Yellow Book | Travelers' Health | CDC". Archived from the original on 2014-12-26.
  14. 1 2 3 4 Schlagenhauf P (June 1999). "Mefloquine for malaria chemoprophylaxis 1992-1998: a review". Journal of Travel Medicine. 6 (2): 122–133. doi: 10.1111/j.1708-8305.1999.tb00843.x . PMID   10381965.
  15. ↑ Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D (October 2017). "Mefloquine for preventing malaria during travel to endemic areas". The Cochrane Database of Systematic Reviews. 2017 (10): CD006491. doi:10.1002/14651858.CD006491.pub4. PMC   5686653 . PMID   29083100.
  16. 1 2 3 4 5 6 "Lariam medication guide" (PDF). Hoffman La Roche. Archived (PDF) from the original on 2 October 2013. Retrieved 27 September 2013.
  17. ↑ "www.cdc.gov" (PDF). Archived (PDF) from the original on 2015-02-09.
  18. ↑ "Malaria Information". Traveldoctor. Archived from the original on 28 June 2016. Retrieved 9 July 2016.
  19. ↑ Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. (2004). "Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number". Lancet. 364 (9432): 438–447. doi:10.1016/S0140-6736(04)16767-6. PMC   4337987 . PMID   15288742.
  20. ↑ "Mefloquine hydrochloride tablet". DailyMed. 31 May 2016. Retrieved 8 September 2020.
  21. ↑ "www.fda.gov" (PDF). Food and Drug Administration . Archived (PDF) from the original on 2014-06-30.
  22. ↑ "FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects". Food and Drug Administration .
  23. ↑ AlKadi HO (2007). "Antimalarial drug toxicity: a review". Chemotherapy. 53 (6): 385–391. doi:10.1159/000109767. PMID   17934257. S2CID   7888082.
  24. 1 2 "Mefloquine" (PDF). Medicines for the Prevention of Malaria While Traveling. Atlanta, Georgia: Centers for Disease Control and Prevention. 2019. Retrieved 2019-03-30.
  25. 1 2 González R, Hellgren U, Greenwood B, Menéndez C (February 2014). "Mefloquine safety and tolerability in pregnancy: a systematic literature review". Malaria Journal. 13: 75. doi: 10.1186/1475-2875-13-75 . PMC   3942617 . PMID   24581338.
  26. ↑ Croft AM (July 2010). "Malaria: prevention in travellers". BMJ Clinical Evidence. 2010. PMC   3217660 . PMID   21418669.
  27. ↑ Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, et al. (June 2012). "Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy". Clinical Infectious Diseases. 54 (11): e124–e131. doi:10.1093/cid/cis215. PMC   3348951 . PMID   22495078.
  28. ↑ "Lariam product monogram" (PDF). Hoffman La Roche Limited. p. 3. Archived from the original (PDF) on 17 December 2011. Retrieved 24 April 2011.
  29. ↑ "Lariam product monogram" (PDF). Hoffman La Roche Limited. p. 4. Archived from the original (PDF) on 17 December 2011. Retrieved 24 April 2011.
  30. ↑ "Lariam product monogram" (PDF). Hoffman La Roche Limited. p. 6. Archived from the original (PDF) on 17 December 2011. Retrieved 24 April 2011.
  31. ↑ "Lariam product monogram" (PDF). Hoffman La Roche Limited. p. 18. Archived from the original (PDF) on 17 December 2011. Retrieved 24 April 2011.
  32. ↑ "Roche Submission to Committee Secretary Senate Foreign Affairs Australia".
  33. 1 2 "'It's not a benign drug - it has ruined my life'". Guardian News & Media Limited. 24 October 2002.
  34. ↑ Adams S (6 September 2017). "Cure or curse?". Canvet Publications Ltd. Legion Magazine.
  35. ↑ Hennequin C, Bourée P, Bazin N, Bisaro F, Feline A (October 1994). "Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine". Archives of Internal Medicine. 154 (20): 2360–2362. doi:10.1001/archinte.1994.00420200116012. PMID   7944858.
  36. ↑ Speich R, Haller A (July 1994). "Central anticholinergic syndrome with the antimalarial drug mefloquine". The New England Journal of Medicine. 331 (1): 57–58. doi: 10.1056/NEJM199407073310120 . PMID   8202114.
  37. ↑ Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, et al. (October 2001). "Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study". Clinical Infectious Diseases. 33 (7): 1015–1021. doi: 10.1086/322694 . PMID   11528574.
  38. 1 2 3 4 5 6 7 8 "Germany bans drug linked to brain damage, ramps up pressure on Canada". iPolitics. 9 December 2016.
  39. ↑ "Did Lariam send Cambridge student Alana Cutland to her death… and what anti-malarials should children take on their gap year?". Telegraph Media Group Limited. 3 August 2019.
  40. ↑ Haines A (18 October 2019). "Canadian soldiers allege anti-malaria medication left them with intense rage, suicidal ideations". W5. Retrieved 16 April 2020.
  41. ↑ "Lariam (Mefloquine) in the Armed Forces".
  42. ↑ Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS (April 2011). "Mefloquine in the treatment of progressive multifocal leukoencephalopathy". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 452–455. doi:10.1136/jnnp.2009.190652. PMID   20562463. S2CID   19877728. Archived from the original on 2012-03-21. Retrieved 2011-10-16.
  43. ↑ McArdle JJ, Sellin LC, Coakley KM, Potian JG, Quinones-Lopez MC, Rosenfeld CA, et al. (December 2005). "Mefloquine inhibits cholinesterases at the mouse neuromuscular junction". Neuropharmacology. 49 (8): 1132–1139. doi:10.1016/j.neuropharm.2005.06.011. PMID   16081111. S2CID   28938736.
  44. ↑ McArdle JJ, Sellin LC, Coakley KM, Potian JG, Hognason K (March 2006). "Mefloquine selectively increases asynchronous acetylcholine release from motor nerve terminals". Neuropharmacology. 50 (3): 345–353. doi:10.1016/j.neuropharm.2005.09.011. PMID   16288931. S2CID   13245990.
  45. ↑ Zhou C, Xiao C, McArdle JJ, Ye JH (June 2006). "Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase". The Journal of Pharmacology and Experimental Therapeutics. 317 (3): 1155–1160. doi:10.1124/JPET.106.101923. PMID   16501066. S2CID   22205111.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.